NCT06853171View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

July 22, 2025

Study Completion Date

July 22, 2025

Conditions
Psychiatric Disorders
Interventions
DRUG

KarXT

Specified dose on specified days

DRUG

KarX-EC

Specified dose on specified days

Trial Locations (4)

30030

Local Institution - 0007, Decatur

66212

Local Institution - 0008, Overland Park

72204

Local Institution - 0005, Little Rock

92868

Local Institution - 0006, Orange

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY